Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Alzheimer's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 83 articles:
HTML format
Text format



Single Articles


    June 2017
  1. ZHAN X
    Author response: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed     Text format    


  2. MENTE K
    Letter re: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed     Text format    


  3. BUCKLEY RF, Schultz AP, Hedden T, Papp KV, et al
    Functional network integrity presages cognitive decline in preclinical Alzheimer disease.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004059.
    PubMed     Text format     Abstract available


    May 2017
  4. GIANNINI LAA, Irwin DJ, McMillan CT, Ash S, et al
    Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia.
    Neurology. 2017 May 17. pii: 10.1212/WNL.0000000000004034.
    PubMed     Text format     Abstract available


  5. BOOTS EA, Schultz SA, Clark LR, Racine AM, et al
    BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003980.
    PubMed     Text format     Abstract available


    April 2017
  6. SCHULTZ SA, Boots EA, Darst BF, Zetterberg H, et al
    Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD.
    Neurology. 2017;88:1650-1658.
    PubMed     Text format     Abstract available


  7. NG KP, Pascoal TA, Mathotaarachchi S, Chung CO, et al
    Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017 Apr 12. pii: 10.1212/WNL.0000000000003916.
    PubMed     Text format     Abstract available


  8. PETERSEN RC, Thomas RG, Aisen PS, Mohs RC, et al
    Randomized controlled trials in mild cognitive impairment: Sources of variability.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003907.
    PubMed     Text format     Abstract available


  9. RELKIN NR, Thomas RG, Rissman RA, Brewer JB, et al
    A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003904.
    PubMed     Text format     Abstract available


    March 2017
  10. PAPP KV, Rentz DM, Mormino EC, Schultz AP, et al
    Cued memory decline in biomarker-defined preclinical Alzheimer disease.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003812.
    PubMed     Text format     Abstract available


    February 2017
  11. DAY GS, Lim TS, Hassenstab J, Goate AM, et al
    Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003770.
    PubMed     Text format     Abstract available


  12. TOSTO G, Bird TD, Tsuang D, Bennett DA, et al
    Polygenic risk scores in familial Alzheimer disease.
    Neurology. 2017 Feb 17. pii: 10.1212/WNL.0000000000003734.
    PubMed     Text format     Abstract available


  13. IMTIAZ B, Tuppurainen M, Rikkonen T, Kivipelto M, et al
    Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study.
    Neurology. 2017 Feb 15. pii: 10.1212/WNL.0000000000003696.
    PubMed     Text format     Abstract available


  14. CHEN J, Yu JT, Wojta K, Wang HF, et al
    Genome-wide association study identifies MAPT locus influencing human plasma tau levels.
    Neurology. 2017;88:669-676.
    PubMed     Text format     Abstract available


  15. FRANZMEIER N, Duering M, Weiner M, Dichgans M, et al
    Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003711.
    PubMed     Text format     Abstract available


  16. KREISL WC, Lawrence R, Page E, Teich AF, et al
    11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003693.
    PubMed     Text format    


    January 2017
  17. FEDOROVA TD, Seidelin LB, Knudsen K, Schacht AC, et al
    Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study.
    Neurology. 2017 Jan 18. pii: 10.1212/WNL.0000000000003633.
    PubMed     Text format     Abstract available


  18. THOMAS AJ, Attems J, Colloby SJ, O'Brien JT, et al
    Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.
    Neurology. 2017;88:276-283.
    PubMed     Text format     Abstract available


    December 2016
  19. ENNIS GE, An Y, Resnick SM, Ferrucci L, et al
    Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003537.
    PubMed     Text format     Abstract available


    November 2016
  20. MOKRY LE, Ross S, Morris JA, Manousaki D, et al
    Genetically decreased vitamin D and risk of Alzheimer disease.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003430.
    PubMed     Text format     Abstract available


  21. HOHMAN TJ, McLaren DG, Mormino EC, Gifford KA, et al
    Asymptomatic Alzheimer disease: Defining resilience.
    Neurology. 2016 Nov 4. pii: 10.1212/WNL.0000000000003397.
    PubMed     Text format     Abstract available


    October 2016
  22. KIKUCHI A, Okamura N, Hasegawa T, Harada R, et al
    In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.
    Neurology. 2016 Oct 28. pii: 10.1212/WNL.0000000000003375.
    PubMed     Text format     Abstract available


  23. ZHAN X, Stamova B, Jin LW, DeCarli C, et al
    Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2016 Oct 26. pii: 10.1212/WNL.0000000000003391.
    PubMed     Text format     Abstract available


  24. WESTON PS, Nicholas JM, Lehmann M, Ryan NS, et al
    Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003322.
    PubMed     Text format     Abstract available


  25. MATTIS PJ, Niethammer M, Sako W, Tang CC, et al
    Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003285.
    PubMed     Text format     Abstract available


    September 2016
  26. MATTSSON N, Zetterberg H, Janelidze S, Insel PS, et al
    Plasma tau in Alzheimer disease.
    Neurology. 2016 Sep 30. pii: 10.1212/WNL.0000000000003246.
    PubMed     Text format     Abstract available


    August 2016
  27. ROGALSKI E, Sridhar J, Rader B, Martersteck A, et al
    Aphasic variant of Alzheimer disease: Clinical, anatomic, and genetic features.
    Neurology. 2016 Aug 26. pii: 10.1212/WNL.0000000000003165.
    PubMed     Text format     Abstract available


  28. BURNHAM SC, Rowe CC, Baker D, Bush AI, et al
    Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up.
    Neurology. 2016 Aug 17. pii: 10.1212/WNL.0000000000003094.
    PubMed     Text format     Abstract available


    July 2016
  29. ZAREA A, Charbonnier C, Rovelet-Lecrux A, Nicolas G, et al
    Seizures in dominantly inherited Alzheimer disease.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003048.
    PubMed     Text format     Abstract available


  30. KNOPMAN DS, Jack CR Jr, Wiste HJ, Weigand SD, et al
    Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002979.
    PubMed     Text format     Abstract available


  31. KNICKMEYER RC, Ross ME
    Imaging and rare APOE alleles: Alzheimer disease as a developmental disorder.
    Neurology. 2016 Jul 13. pii: 10.1212/WNL.0000000000002956.
    PubMed     Text format    


  32. MORMINO EC, Sperling RA, Holmes AJ, Buckner RL, et al
    Polygenic risk of Alzheimer disease is associated with early- and late-life processes.
    Neurology. 2016 Jul 6. pii: 10.1212/WNL.0000000000002922.
    PubMed     Text format     Abstract available


  33. JACK CR JR, Bennett DA, Blennow K, Carrillo MC, et al
    A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.
    Neurology. 2016 Jul 1. pii: 10.1212/WNL.0000000000002923.
    PubMed     Text format     Abstract available


  34. FARFEL JM, Yu L, Buchman AS, Schneider JA, et al
    Relation of genomic variants for Alzheimer disease dementia to common neuropathologies.
    Neurology. 2016 Jul 1. pii: 10.1212/WNL.0000000000002909.
    PubMed     Text format     Abstract available


    June 2016
  35. CHO H, Choi JY, Hwang MS, Lee JH, et al
    Tau PET in Alzheimer disease and mild cognitive impairment.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002892.
    PubMed     Text format     Abstract available


  36. COLLOBY SJ, McKeith IG, Burn DJ, Wyper DJ, et al
    Cholinergic and perfusion brain networks in Parkinson disease dementia.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002839.
    PubMed     Text format     Abstract available


    May 2016
  37. VOEVODSKAYA O, Sundgren PC, Strandberg O, Zetterberg H, et al
    Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
    Neurology. 2016;86:1754-61.
    PubMed     Text format     Abstract available


    April 2016
  38. VAN DEN BOSSCHE T, Sleegers K, Cuyvers E, Engelborghs S, et al
    Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002628.
    PubMed     Text format     Abstract available


  39. SWERDLOW RH
    Rare ABCA7 variants in Alzheimer disease: Guilt by association.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002630.
    PubMed     Text format    


  40. LE GUENNEC K, Nicolas G, Quenez O, Charbonnier C, et al
    ABCA7 rare variants and Alzheimer disease risk.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002627.
    PubMed     Text format     Abstract available


    March 2016
  41. LIM YY, Laws SM, Villemagne VL, Pietrzak RH, et al
    Abeta-related memory decline in APOE epsilon4 noncarriers: Implications for Alzheimer disease.
    Neurology. 2016 Mar 30. pii: 10.1212/WNL.0000000000002604.
    PubMed     Text format     Abstract available


  42. XIONG C, Jasielec MS, Weng H, Fagan AM, et al
    Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002593.
    PubMed     Text format     Abstract available


  43. GUTIERREZ J, Honig L, Elkind MS, Mohr JP, et al
    Brain arterial aging and its relationship to Alzheimer dementia.
    Neurology. 2016 Mar 16. pii: 10.1212/WNL.0000000000002590.
    PubMed     Text format     Abstract available


  44. WHITE LR, Edland SD, Hemmy LS, Montine KS, et al
    Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies.
    Neurology. 2016;86:1000-8.
    PubMed     Text format     Abstract available


  45. LANDAU SM, Horng A, Fero A, Jagust WJ, et al
    Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
    Neurology. 2016 Mar 11. pii: 10.1212/WNL.0000000000002576.
    PubMed     Text format     Abstract available


    February 2016
  46. VEMURI P, Lesnick TG, Przybelski SA, Knopman DS, et al
    Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study.
    Neurology. 2016 Feb 24. pii: 10.1212/WNL.0000000000002490.
    PubMed     Text format     Abstract available


  47. GROSSMAN-KAHN R
    Reflections: Neurology and The Humanities. Charades with Alzheimer disease.
    Neurology. 2016;86:e73-4.
    PubMed     Text format    


  48. RANASINGHE KG, Rankin KP, Lobach IV, Kramer JH, et al
    Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage.
    Neurology. 2016;86:600-10.
    PubMed     Text format     Abstract available


    January 2016
  49. WELLINGTON H, Paterson RW, Portelius E, Tornqvist U, et al
    Increased CSF neurogranin concentration is specific to Alzheimer disease.
    Neurology. 2016 Jan 29. pii: 10.1212/WNL.0000000000002423.
    PubMed     Text format     Abstract available


  50. BEERI MS, Sonnen J
    Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression.
    Neurology. 2016 Jan 27. pii: 10.1212/WNL.0000000000002389.
    PubMed     Text format    


  51. DEL CAMPO N, Payoux P, Djilali A, Delrieu J, et al
    Relationship of regional brain beta-amyloid to gait speed.
    Neurology. 2016;86:36-43.
    PubMed     Text format     Abstract available


    December 2015

  52. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial.
    Neurology. 2015;85:2084.
    PubMed     Text format    


  53. TUFAN AN, Tufan F, Holmes C
    Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial.
    Neurology. 2015;85:2083-4.
    PubMed     Text format    


  54. HOLMES C
    Author Response.
    Neurology. 2015;85:2084.
    PubMed     Text format    


  55. BOYLE PA, Yu L, Nag S, Leurgans S, et al
    Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons.
    Neurology. 2015;85:1930-6.
    PubMed     Text format     Abstract available


    November 2015
  56. HENDERSON VW, Ala T, Sainani KL, Bernstein AL, et al
    Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial.
    Neurology. 2015 Nov 4. pii: 10.1212/WNL.0000000000002171.
    PubMed     Text format     Abstract available


    October 2015
  57. ZWAN MD, Rinne JO, Hasselbalch SG, Nordberg A, et al
    Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002081.
    PubMed     Text format     Abstract available


  58. AHMED RM, Latheef S, Bartley L, Irish M, et al
    Eating behavior in frontotemporal dementia: Peripheral hormones vs hypothalamic pathology.
    Neurology. 2015;85:1310-7.
    PubMed     Text format     Abstract available


    September 2015
  59. MORAN C, Beare R, Phan TG, Bruce DG, et al
    Type 2 diabetes mellitus and biomarkers of neurodegeneration.
    Neurology. 2015;85:1123-30.
    PubMed     Text format     Abstract available


  60. LANDY KM, Salmon DP, Galasko D, Filoteo JV, et al
    Motion discrimination in dementia with Lewy bodies and Alzheimer disease.
    Neurology. 2015 Sep 23. pii: 10.1212/WNL.0000000000002028.
    PubMed     Text format     Abstract available


  61. TURNER RS, Thomas RG, Craft S, van Dyck CH, et al
    A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.
    Neurology. 2015 Sep 11. pii: 10.1212/WNL.0000000000002035.
    PubMed     Text format     Abstract available


  62. PALMQVIST S, Zetterberg H, Mattsson N, Johansson P, et al
    Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000001991.
    PubMed     Text format     Abstract available


    August 2015
  63. KNOPMAN DS
    Is dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease?
    Neurology. 2015 Aug 5. pii: 10.1212/WNL.0000000000001897.
    PubMed     Text format    


  64. WANG F, Gordon BA, Ryman DC, Ma S, et al
    Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease.
    Neurology. 2015 Aug 5. pii: 10.1212/WNL.0000000000001903.
    PubMed     Text format     Abstract available


    July 2015
  65. CHILDRESS MD, Chen DT
    Art and Alzheimer dementia: A museum experience for patients may benefit medical students.
    Neurology. 2015 Jul 29. pii: 10.1212/WNL.0000000000001874.
    PubMed     Text format    


  66. FICHERA M, Bernasconi MP, Martinelli V, Comi G, et al
    Drawing in Alzheimer-type dementia.
    Neurology. 2015;85:386-7.
    PubMed     Text format    


  67. YONG KX, Rajdev K, Shakespeare TJ, Leff AP, et al
    Facilitating text reading in posterior cortical atrophy.
    Neurology. 2015;85:339-48.
    PubMed     Text format     Abstract available


  68. TIFRATENE K, Robert P, Metelkina A, Pradier C, et al
    Progression of mild cognitive impairment to dementia due to AD in clinical settings.
    Neurology. 2015;85:331-8.
    PubMed     Text format     Abstract available


  69. BREITNER JC
    Yet another "disconnect" between amyloid and Alzheimer disease?
    Neurology. 2015 Jul 24. pii: 10.1212/WNL.0000000000001871.
    PubMed     Text format    


  70. LIU E, Schmidt ME, Margolin R, Sperling R, et al
    Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
    Neurology. 2015 Jul 24. pii: 10.1212/WNL.0000000000001877.
    PubMed     Text format     Abstract available


  71. CASELLI RJ, Coon EA, Johansson L
    Midlife personality and risk of Alzheimer disease and distress: A 38-year follow-up.
    Neurology. 2015;85:298-9.
    PubMed     Text format    


  72. ALCOLEA D, Martinez-Lage P, Sanchez-Juan P, Olazaran J, et al
    Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
    Neurology. 2015 Jul 15. pii: 10.1212/WNL.0000000000001859.
    PubMed     Text format     Abstract available


  73. BARNES LL, Leurgans S, Aggarwal NT, Shah RC, et al
    Mixed pathology is more likely in black than white decedents with Alzheimer dementia.
    Neurology. 2015 Jul 15. pii: 10.1212/WNL.0000000000001834.
    PubMed     Text format     Abstract available


  74. TOLEDO JB, Bjerke M, Chen K, Rozycki M, et al
    Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.
    Neurology. 2015;85:144-53.
    PubMed     Text format     Abstract available


  75. AMARIGLIO RE, Mormino EC, Pietras AC, Marshall GA, et al
    Subjective cognitive concerns, amyloid-beta, and neurodegeneration in clinically normal elderly.
    Neurology. 2015;85:56-62.
    PubMed     Text format     Abstract available


    June 2015
  76. RAJAN KB, Wilson RS, Weuve J, Barnes LL, et al
    Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia.
    Neurology. 2015 Jun 24. pii: 10.1212/WNL.0000000000001774.
    PubMed     Text format     Abstract available


  77. GOETZL EJ, Boxer A, Schwartz JB, Abner EL, et al
    Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease.
    Neurology. 2015 Jun 10. pii: 10.1212/WNL.0000000000001702.
    PubMed     Text format     Abstract available


  78. GIDICSIN CM, Maye JE, Locascio JJ, Pepin LC, et al
    Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers.
    Neurology. 2015 Jun 10. pii: 10.1212/WNL.0000000000001704.
    PubMed     Text format     Abstract available


    May 2015
  79. MASSIMO L, Zee J, Xie SX, McMillan CT, et al
    Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration.
    Neurology. 2015;84:2070-5.
    PubMed     Text format     Abstract available


  80. OSORIO RS, Gumb T, Pirraglia E, Varga AW, et al
    Sleep-disordered breathing advances cognitive decline in the elderly.
    Neurology. 2015;84:1964-71.
    PubMed     Text format     Abstract available


    April 2015
  81. FOURNIER CN, Gearing M, Upadhyayula SR, Klein M, et al
    Head injury does not alter disease progression or neuropathologic outcomes in ALS.
    Neurology. 2015;84:1788-95.
    PubMed     Text format     Abstract available


  82. KIM SY, Karlawish J, Berkman BE
    Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
    Neurology. 2015;84:1488-94.
    PubMed     Text format     Abstract available


    March 2015
  83. WOLFSGRUBER S, Jessen F, Koppara A, Kleineidam L, et al
    Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.
    Neurology. 2015;84:1261-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: